Mechanism
Thymosin Alpha-1 is a naturally occurring fragment of prothymosin alpha, first isolated from thymic tissue. Rather than acting on a single receptor, it nudges several arms of the immune system toward a more coordinated response — which is why its clearest signals appear in settings of immune weakness rather than in otherwise healthy people.
| Mechanism | Detail |
|---|---|
| T-cell maturation | Promotes differentiation and maturation of T-lymphocytes from precursors, helping restore T-cell counts and function in immunocompromised states. |
| Dendritic cell & antigen priming | Enhances dendritic cell activity and antigen presentation, sharpening the bridge between innate and adaptive immunity — the basis for its use as a vaccine adjuvant. |
| Toll-like receptor signaling | Acts as an agonist at TLR2 and TLR9, activating pathways that boost production of IL-2, interferon-gamma and other cytokines. |
| NK cell & cytokine modulation | Increases natural killer cell activity and can help rebalance cytokine output, dampening excessive inflammation while supporting antiviral responses. |
Evidence Summary
Thymosin Alpha-1 has an unusually deep clinical file for a peptide in the RUO market — decades of international trials, largely in hepatitis and as an adjunct to immune-compromising treatments. The quality is strongest for its approved indications and thins for the broader “immune-boosting” uses it is marketed for domestically.
| Research Area | Evidence | Study Type | Notes |
|---|---|---|---|
| Chronic hepatitis B | Basis for intl. approval | Human RCTs | Response often builds after therapy ends; effect sizes modest but reproducible. |
| Chronic hepatitis C (adjunct) | Studied with antivirals | Human RCTs | Benefit largely as an add-on; partly superseded by modern direct-acting antivirals. |
| Vaccine adjuvant / immune support | Improved vaccine response | Human trials | Approved for immune enhancement in some countries; clearest in weakened immune systems. |
| Sepsis | Mixed mortality signals | Human RCTs | Large China-based trials; heterogeneous, definitive evidence still pending. |
| Cancer treatment adjunct | Explored alongside chemo | Human trials | To reduce immune suppression; not a standalone therapy, evidence mixed. |
| General wellness / anti-aging | No controlled healthy-adult trials | Extrapolation | Popular community use, but approved data does not speak to healthy adults. |
| Human clinical trials (overall) | Thousands of subjects, decades | Regulatory record | Among the most clinically documented peptides sold RUO in the US — but that is not US FDA approval. |
Divergence — What This Means
A real drug abroad, extrapolated to wellness at home.
Thymosin Alpha-1 is a real, approved drug abroad with a substantial trial history — but almost all of that evidence comes from sick populations (hepatitis, sepsis, cancer, dialysis, the elderly).
The US wellness community extrapolates from that to general “immune optimization,” longevity and post-illness recovery in otherwise healthy people, where there is essentially no controlled data. Divergence is moderate because the biology and safety record are genuine — but “approved for hepatitis B abroad” is not the same claim as “proven to boost a healthy person’s immune system.”
The US wellness community extrapolates from that to general “immune optimization,” longevity and post-illness recovery in otherwise healthy people, where there is essentially no controlled data. Divergence is moderate because the biology and safety record are genuine — but “approved for hepatitis B abroad” is not the same claim as “proven to boost a healthy person’s immune system.”
Dose Reference
Not medical advice. Not instruction for human use. For reference only.
Approved reference dose
1.6 mg
per injection (hepatitis B labeling)
Frequency
2× / week
subcutaneous, per approved protocols
Route
Subcutaneous
reconstituted from lyophilized powder
Course length
Weeks–months
indication-dependent in trials
Figures reflect the internationally approved hepatitis B regimen and are provided as a factual reference only — not a protocol, endorsement, or medical advice. Community RUO use varies widely and is not standardized.
Safety Profile
Across decades of trials, Thymosin Alpha-1 has a reassuring tolerability profile — one reason it reached approval in so many markets. Most reported effects are mild and local.
Animal / preclinical — signals observed
Injection-site reactions (redness, discomfort, transient swelling)
Generally well tolerated in controlled trials, low discontinuation rates
Occasional short-lived flu-like or fatigue sensations
Rare hypersensitivity reactions
What is not known (human)
Long-term effects of chronic use in healthy adults (no trial data)
Safety in pregnancy, breastfeeding, and pediatric use
Effects in autoimmune conditions, where immune stimulation could theoretically matter
Purity and dosing consistency of RUO/compounded material sold outside approved channels
The favorable safety record comes from regulated, pharmaceutical-grade product used under medical supervision — it does not automatically transfer to unregulated research-only material.
Regulatory Status — Updated July 2026
Approved abroad, research-only at home
Thymosin Alpha-1 is approved and marketed internationally as Zadaxin (thymalfasin) in roughly 30 or more countries for indications including hepatitis B and C, immune support and vaccine enhancement. In the United States, however, it is not FDA-approved and is sold only research-use-only. It was not part of the July 2026 PCAC 503A review — it has been named among peptides flagged for possible reconsideration, but was not formally reviewed or voted on. Track current status →
Where to Source
Source research-grade Thymosin Alpha-1
Lone Star Peptide Co. — Houston, TX. Batch-specific COAs on every vial, same-day domestic shipping, and third-party testing. The most transparent way to source Thymosin Alpha-1.
Peptide Atlas is created by Lone Star Peptide Co. — a disclosed placement. Full disclosure.
Frequently Asked Questions
No. It is not approved by the FDA and is sold in the US research-use-only. It is, however, an approved pharmaceutical in many other countries under the name Zadaxin (thymalfasin).
Yes — Zadaxin is the international brand name for thymalfasin, which is Thymosin Alpha-1. It is approved in roughly 30 or more countries, primarily for chronic hepatitis B and C, as a vaccine adjuvant and for immune support. This gives it a genuine clinical record many RUO peptides lack.
No. It was not part of the July 2026 PCAC 503A review and was not formally reviewed or voted on. It has been named among peptides flagged for possible reconsideration, so its US status is best described as pending rather than decided.
Not necessarily. The approved evidence comes almost entirely from people with hepatitis, sepsis, cancer or weakened immune systems. There is little to no controlled data in healthy adults using it for general wellness or anti-aging, so those uses remain extrapolation.
Compare Thymosin Alpha-1